Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

42070

registered interest
date	10/03/2014
answering body	Department for Transport
answering dept id	27
answering dept short name
answering dept sort name
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what sanctions have been applied in the last 12 months for poor quality performance on the Birmingham Cross City line by London Midland.
tabling member printed	Lord Hunt of Kings Heath
uin	HL5871
answer	answer is ministerial correction date of answer 24/03/2014 answer text We have applied no sanctions against London Midland in regard to performance on the Birmingham Cross City line; we do not disaggregate performance by the train operators to that level. In the autumn of 2012 London Midland experienced a high number of cancellations, largely due to issues with availability of train crew. As a result, they breached the terms of their Franchise Agreement, and a remedial plan and package of benefits was agreed with the Department. As the Secretary of State for Transport announced to the House on 20 December 2012, this package included passenger benefits of: 500,000 discounted tickets, free travel for season ticket holders (worth up to c.£5.4m), capital investment, and additional driver training investment worth a combined £6.25m answering member printed Baroness Kramer question first answered 24/03/2014 12:00:00 answering member 1557 label Biography information for Baroness Kramer
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

79646

registered interest
date	28/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neurofibromatosis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government out of all known patients with neurofibromatosis Type 1, how many were treated in the last 12 months at the two designated national specialist care centres.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1538
answer	answer is ministerial correction date of answer 18/08/2014 answer text <p>Whilst the number of people with neurofibromatosis Type 1 (NF1) in England is estimated to number 11,267, the number of patients with a confirmed diagnosis is not collected.</p><p> </p><p>In the following table we have provided the number of finished admission episodes (FAEs) for patients with a primary diagnosis of NF1 who were treated at the two national specialist centres in 2012-13, the most recent period for which data is available. An FAE is a continuous period of admitted patient care under one consultant within one health care provider. It should be noted the figures do not represent a count of patients, as a person may have more than one episode of care within the same stay in hospital or in different stays in the same year.</p><p> </p><p> </p><table><tbody><tr><td colspan="2"><p>FAEs in 2012-13 for patients with primary or secondary diagnosis of NF1 (non-malignant)</p><p> </p></td></tr><tr><td><p>Trust</p></td><td><p>Numbers</p></td></tr><tr><td><p>Central Manchester University Hospitals NHS Foundation Trust</p></td><td><p>213</p></td></tr><tr><td><p>Guys and St. Thomas’ NHS Foundation Trust</p></td><td><p>124</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p> </p><p> </p><p><em>Source:</em> Hospital Episode Statistics (HES), Health and Social Care Information Centre</p><p> </p><p>Information concerning the number of patients waiting to be treated at the two national centres is not available.</p><p> </p> answering member printed Earl Howe grouped question UIN HL1539 question first answered 18/08/2014 10:18:05 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

79647

registered interest
date	28/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neurofibromatosis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how many patients with neurofibromatosis Type 1 are waiting to be treated at the two designated national specialist care centres.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1539
answer	answer is ministerial correction date of answer 18/08/2014 answer text <p>Whilst the number of people with neurofibromatosis Type 1 (NF1) in England is estimated to number 11,267, the number of patients with a confirmed diagnosis is not collected.</p><p> </p><p>In the following table we have provided the number of finished admission episodes (FAEs) for patients with a primary diagnosis of NF1 who were treated at the two national specialist centres in 2012-13, the most recent period for which data is available. An FAE is a continuous period of admitted patient care under one consultant within one health care provider. It should be noted the figures do not represent a count of patients, as a person may have more than one episode of care within the same stay in hospital or in different stays in the same year.</p><p> </p><p> </p><table><tbody><tr><td colspan="2"><p>FAEs in 2012-13 for patients with primary or secondary diagnosis of NF1 (non-malignant)</p><p> </p></td></tr><tr><td><p>Trust</p></td><td><p>Numbers</p></td></tr><tr><td><p>Central Manchester University Hospitals NHS Foundation Trust</p></td><td><p>213</p></td></tr><tr><td><p>Guys and St. Thomas’ NHS Foundation Trust</p></td><td><p>124</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p> </p><p> </p><p><em>Source:</em> Hospital Episode Statistics (HES), Health and Social Care Information Centre</p><p> </p><p>Information concerning the number of patients waiting to be treated at the two national centres is not available.</p><p> </p> answering member printed Earl Howe grouped question UIN HL1538 question first answered 18/08/2014 10:18:04 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

61924

registered interest
date	16/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Gender Recognition
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what action they have taken to address transgender patient discrimination in the National Health Service.
tabling member printed	Lord Hunt of Kings Heath
uin	HL342
answer	answer is ministerial correction date of answer 25/06/2014 answer text <p>We expect people with transgender issues to have the same access to National Health Service treatment, including mental health services, as anybody else in the population. Mental Health has been a priority for this Government for several years now. We made this commitment explicit in the Health and Social Care Act 2012 which, for the first time, creates equal status for mental and physical health across Government and for the NHS and social care.</p><p> </p><p>Since April 2013, gender identity services have been commissioned by NHS England. NHS England will continue to work with the transgendered community, clinical experts and stakeholders through the clinical reference group for gender identity services, to produce a single and consistent policy for the whole of England.</p><p> </p><p>In order to ensure equitable access to services, an England-wide Interim Protocol was consulted on, developed and became operational on 1 November 2013. The Protocol is based on the previously published and well received Scottish Protocol. The Protocol relies on the publication of the Inter-Collegiate “Good practice guidelines for the treatment of adults with gender dysphoria” published at the end of October 2013. A fully consulted policy document and service specifications will be published during 2014.</p><p> </p><p>In addition, NHS England has commissioned a review of transgendered patients' access to the NHS. This review has considered all aspects of access to NHS services and is currently being finalised in readiness for publishing.</p> answering member printed Earl Howe grouped question UIN HL343 question first answered 25/06/2014 12:16:07 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

61925

registered interest
date	16/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Gender Recognition
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what action they are taking to support transgenderpeople's mental health and wellbeing.
tabling member printed	Lord Hunt of Kings Heath
uin	HL343
answer	answer is ministerial correction date of answer 25/06/2014 answer text <p>We expect people with transgender issues to have the same access to National Health Service treatment, including mental health services, as anybody else in the population. Mental Health has been a priority for this Government for several years now. We made this commitment explicit in the Health and Social Care Act 2012 which, for the first time, creates equal status for mental and physical health across Government and for the NHS and social care.</p><p> </p><p>Since April 2013, gender identity services have been commissioned by NHS England. NHS England will continue to work with the transgendered community, clinical experts and stakeholders through the clinical reference group for gender identity services, to produce a single and consistent policy for the whole of England.</p><p> </p><p>In order to ensure equitable access to services, an England-wide Interim Protocol was consulted on, developed and became operational on 1 November 2013. The Protocol is based on the previously published and well received Scottish Protocol. The Protocol relies on the publication of the Inter-Collegiate “Good practice guidelines for the treatment of adults with gender dysphoria” published at the end of October 2013. A fully consulted policy document and service specifications will be published during 2014.</p><p> </p><p>In addition, NHS England has commissioned a review of transgendered patients' access to the NHS. This review has considered all aspects of access to NHS services and is currently being finalised in readiness for publishing.</p> answering member printed Earl Howe grouped question UIN HL342 question first answered 25/06/2014 12:16:06 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

61923

registered interest
date	16/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Domestic Accidents
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what is their estimate of the proportion of accident and emergency attendances caused by accidents in the home.
tabling member printed	Lord Hunt of Kings Heath
uin	HL341
answer	answer is ministerial correction date of answer 19/06/2014 answer text <p>This information is not available centrally.</p> answering member printed Earl Howe question first answered 19/06/2014 11:44:47 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

79468

registered interest
date	22/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Gastrointestinal Cancer
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what is their assessment of the current National Health Service ability to meet the needs of paediatric, adolescent, wild-type and syndromic gastrointestinal stromal tumour cancer patients.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1367
answer	answer is ministerial correction date of answer 29/07/2014 answer text <p>This Government wants England to lead the world in tackling cancer and ensure the National Health Service is able to meet the needs of all cancer patients. That is why our 2011 Cancer Outcomes Strategy set the ambition to save a further 5,000 lives a year from cancer by 2014-15. The Strategy is backed with more than £750 million over the four year Spending Review period (2011-12 to 2014-15).</p><p> </p><p>A number of treatments have been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of gastrointestinal stromal tumour (GIST) including the paediatric, adolescent, wild-type and syndromic (PAWS) sub-variants.</p><p> </p><p>NHS commissioners are legally required to fund treatments recommended by NICE in its technology appraisal guidance. NICE regularly reviews its guidance to take into account new evidence.</p><p> </p><p>Treatment for PAWS GIST is commissioned through NHS England’s Specialised Services. Treatment for individuals is managed through multi-disciplinary teams. GIST Support UK have in partnership with Addenbrookes Hospital in Cambridge, established a PAWS-GIST clinic that is led by Dr Bulusu working with a United Kingdom national alliance of doctors. NHS England, through its Children’s Cancer and Sarcoma Clinical Reference Groups, is monitoring the clinic as it develops and progresses.</p><p> </p><p>We know how important it is for patients to receive the information they need and a range of initiatives have been used in the NHS, such as information prescriptions, advanced communications training and support for clinical nurse specialists.</p><p> </p><p>NICE guidance on improving outcomes in children and young people with cancer also emphasises the importance of providing patients, families and carers with the information they need.</p><p> </p><p>NHS England has no plans to develop a National Service Framework for paediatric, adolescent, wild-type and syndromic gastrointestinal stromal tumour.</p> answering member printed Earl Howe grouped question UIN HL1368 HL1369 HL1371 question first answered 29/07/2014 13:23:05 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

79469

registered interest
date	22/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Gastrointestinal Cancer
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they will develop a National Service Framework for paediatric, adolescent, wild-type and syndromic gastrointestinal stromal tumour cancer patients.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1368
answer	answer is ministerial correction date of answer 29/07/2014 answer text <p>This Government wants England to lead the world in tackling cancer and ensure the National Health Service is able to meet the needs of all cancer patients. That is why our 2011 Cancer Outcomes Strategy set the ambition to save a further 5,000 lives a year from cancer by 2014-15. The Strategy is backed with more than £750 million over the four year Spending Review period (2011-12 to 2014-15).</p><p> </p><p>A number of treatments have been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of gastrointestinal stromal tumour (GIST) including the paediatric, adolescent, wild-type and syndromic (PAWS) sub-variants.</p><p> </p><p>NHS commissioners are legally required to fund treatments recommended by NICE in its technology appraisal guidance. NICE regularly reviews its guidance to take into account new evidence.</p><p> </p><p>Treatment for PAWS GIST is commissioned through NHS England’s Specialised Services. Treatment for individuals is managed through multi-disciplinary teams. GIST Support UK have in partnership with Addenbrookes Hospital in Cambridge, established a PAWS-GIST clinic that is led by Dr Bulusu working with a United Kingdom national alliance of doctors. NHS England, through its Children’s Cancer and Sarcoma Clinical Reference Groups, is monitoring the clinic as it develops and progresses.</p><p> </p><p>We know how important it is for patients to receive the information they need and a range of initiatives have been used in the NHS, such as information prescriptions, advanced communications training and support for clinical nurse specialists.</p><p> </p><p>NICE guidance on improving outcomes in children and young people with cancer also emphasises the importance of providing patients, families and carers with the information they need.</p><p> </p><p>NHS England has no plans to develop a National Service Framework for paediatric, adolescent, wild-type and syndromic gastrointestinal stromal tumour.</p> answering member printed Earl Howe grouped question UIN HL1367 HL1369 HL1371 question first answered 29/07/2014 13:23:05 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

79470

registered interest
date	22/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Gastrointestinal Cancer
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what information is made available to patients about paediatric, adolescent, wild-type and syndromic gastrointestinal stromal tumours.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1369
answer	answer is ministerial correction date of answer 29/07/2014 answer text <p>This Government wants England to lead the world in tackling cancer and ensure the National Health Service is able to meet the needs of all cancer patients. That is why our 2011 Cancer Outcomes Strategy set the ambition to save a further 5,000 lives a year from cancer by 2014-15. The Strategy is backed with more than £750 million over the four year Spending Review period (2011-12 to 2014-15).</p><p> </p><p>A number of treatments have been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of gastrointestinal stromal tumour (GIST) including the paediatric, adolescent, wild-type and syndromic (PAWS) sub-variants.</p><p> </p><p>NHS commissioners are legally required to fund treatments recommended by NICE in its technology appraisal guidance. NICE regularly reviews its guidance to take into account new evidence.</p><p> </p><p>Treatment for PAWS GIST is commissioned through NHS England’s Specialised Services. Treatment for individuals is managed through multi-disciplinary teams. GIST Support UK have in partnership with Addenbrookes Hospital in Cambridge, established a PAWS-GIST clinic that is led by Dr Bulusu working with a United Kingdom national alliance of doctors. NHS England, through its Children’s Cancer and Sarcoma Clinical Reference Groups, is monitoring the clinic as it develops and progresses.</p><p> </p><p>We know how important it is for patients to receive the information they need and a range of initiatives have been used in the NHS, such as information prescriptions, advanced communications training and support for clinical nurse specialists.</p><p> </p><p>NICE guidance on improving outcomes in children and young people with cancer also emphasises the importance of providing patients, families and carers with the information they need.</p><p> </p><p>NHS England has no plans to develop a National Service Framework for paediatric, adolescent, wild-type and syndromic gastrointestinal stromal tumour.</p> answering member printed Earl Howe grouped question UIN HL1367 HL1368 HL1371 question first answered 29/07/2014 13:23:05 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

79472

registered interest
date	22/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Gastrointestinal Cancer
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what their assessment is of the treatment available for paediatric, adolescent, wild-type and syndromic gastrointestinal stromal tumour cancer patients.
tabling member printed	Lord Hunt of Kings Heath
uin	HL1371
answer	answer is ministerial correction date of answer 29/07/2014 answer text <p>This Government wants England to lead the world in tackling cancer and ensure the National Health Service is able to meet the needs of all cancer patients. That is why our 2011 Cancer Outcomes Strategy set the ambition to save a further 5,000 lives a year from cancer by 2014-15. The Strategy is backed with more than £750 million over the four year Spending Review period (2011-12 to 2014-15).</p><p> </p><p>A number of treatments have been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of gastrointestinal stromal tumour (GIST) including the paediatric, adolescent, wild-type and syndromic (PAWS) sub-variants.</p><p> </p><p>NHS commissioners are legally required to fund treatments recommended by NICE in its technology appraisal guidance. NICE regularly reviews its guidance to take into account new evidence.</p><p> </p><p>Treatment for PAWS GIST is commissioned through NHS England’s Specialised Services. Treatment for individuals is managed through multi-disciplinary teams. GIST Support UK have in partnership with Addenbrookes Hospital in Cambridge, established a PAWS-GIST clinic that is led by Dr Bulusu working with a United Kingdom national alliance of doctors. NHS England, through its Children’s Cancer and Sarcoma Clinical Reference Groups, is monitoring the clinic as it develops and progresses.</p><p> </p><p>We know how important it is for patients to receive the information they need and a range of initiatives have been used in the NHS, such as information prescriptions, advanced communications training and support for clinical nurse specialists.</p><p> </p><p>NICE guidance on improving outcomes in children and young people with cancer also emphasises the importance of providing patients, families and carers with the information they need.</p><p> </p><p>NHS England has no plans to develop a National Service Framework for paediatric, adolescent, wild-type and syndromic gastrointestinal stromal tumour.</p> answering member printed Earl Howe grouped question UIN HL1367 HL1368 HL1369 question first answered 29/07/2014 13:23:06 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath